Clinical Trial Detail

NCT ID NCT02367781
Title A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

lung non-small cell carcinoma

Therapies

Atezolizumab

Carboplatin + Nab-paclitaxel

Age Groups: adult

No variant requirements are available.